Features of aggregometry indicators in male residents of the Stavropol Territory — representatives of the Russian and Armenian ethnic groups receiving hospital treatment
https://doi.org/10.37489/2588-0527-2024-1-14-19
EDN: CSRASK
Abstract
Relevance. The scale of use of acetylsalicylic acid is determined by its use as a means of suppressing platelet aggregation in patients with coronary heart disease. It has been established that the antiplatelet effect in some patients may be weak and insufficient to prevent thrombosis. In this regard, the problem of resistance to acetylsalicylic acid requires more detailed study.
Objective. To study the influence of acetylsalicylic acid on aggregometry indicators in men with the same body weight, belonging to the Russian and Armenian ethnic groups of residents of the Stavropol Territory, who were treated in a specialized hospital.
Material and methods. Men who were treated in the following hospital departments were examined: cardiology department; department of acute coronary syndrome, and department of acute cerebrovascular accidents. Russian ethnic group — 53, Armenian — 24 patients. When forming groups, a body mass index in the range of 33.0±3.9 was considered to be selected patients with similar body weight. Patients received 75 or 100 mg of acetylsalicylic acid per day. In the department of acute coronary syndrome, acetylsalicylic acid was used along with clopidogrel — 75 mg per day. Aggregatometry was performed after 5 days of regular antiplatelet therapy.
Results. In men of the Russian ethnic group who received acetylsalicylic acid at a daily dose of 75 mg, the amplitude of ADP-induced aggregation was statistically significantly higher (Me=13.9 %) than in the Armenian group (Me = 3.0) (p = 0.024). Armenians showed smaller amplitudes of aggregation during induction with ristomycin (33.3 %) than Russians (52.7 %). When using acetylsalicylic acid at a higher dose (100 mg per day), as well as when prescribing two antiplatelet agents, the differences between ethnic groups decreased.
Conclusion. When using acetylsalicylic acid at a dose of 75 mg/day in sick men of the Russian ethnic group, insufficient antiplatelet activity of the drug can be expected.
Keywords
About the Authors
V. A. BaturinRussian Federation
Vladimir A. Baturin, PhD, Dr. Sci. (Med), Professor, Head of the Department of Clinical Pharmacology with the course of DPO,
Stavropol.
Competing Interests:
The authors declare that there is no conflict of interest.
A. V. Ivanova
Russian Federation
Anna V. Ivanova, Assistant of the Department of Clinical Pharmacology with the course of DPO,
Stavropol.
Competing Interests:
The authors declare that there is no conflict of interest.
A. A. Tsarukyan
Russian Federation
Anna A. Tsarukyan, PhD, Cand. Sci. (Med), Associate Professor of the Department of Clinical Pharmacology with the course of DPO,
Stavropol.
Competing Interests:
The authors declare that there is no conflict of interest.
K. A. Muravyov
Russian Federation
Konstantin A. Muravyov, PhD, Dr. Sci. (Med), Professor of the Department of Public Health and Healthcare,
Stavropol.
Competing Interests:
The authors declare that there is no conflict of interest.
References
1. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost. 2003 Aug;1(8):1710-3. doi: 10.1046/j.1538-7836.2003.00284.x.
2. Sulimov VA, Moroz EV. Antiplatelet drug resistance in patients with coronary heart disease. Cardiovascular Therapy and Prevention. 2012;11(6):71-77. (In Russ.). doi: 10.15829/1728-8800-2012-6-71-77.
3. Andreev DA. The significance of platelet functional activity testing in the prevention of cardiovascular complications in patients receiving antiplatelet therapy. Rational Pharmacotherapy in Cardiology. 2014;10(6):679-687. (In Russ.) doi: 10.20996/1819-6446-2014-10-6-679-687
4. Komarov AL, Panchenko EP. Platelet function test for the assessment of thrombosis and bleeding risk in CHD patients taking antiplatelet medications. Russian Journal of Cardiology. 2015; 3 (119): 25-34. (In Russ.). DOI:10.15829/1560-4071-2015-03-25-34
5. Baturin VA, Carukyan AA, Yakovleva NV, El'kanova AI. Etnicheskie osobennosti terapevticheskogo dejstviya serdechno-sosudistyh lekarstvennyh sredstv u zhitelej Stavropol'skogo kraya. Stavropol': Izd. StGMU; 2016. (In Russ.).
6. Baturin VA, Ivanova AV, Carukyan AA, Murav'ev KA. Ocenka antiagregantnogo dejstviya acetilsalicilovoj kisloty v zavisimosti ot massy tela bol'nyh. Sbornik tezisov VI S"ezda terapevtov SKFO. Stavropol' 28-29 aprelya 2022: 9-10. (In Russ.).
7. Lomakin NV, Buryachkovskaya LI, Sumarokov AB, et al. Laboratory definition of “therapeutic window” of antiplatelet drugs. Results of the Real-life Acute Coronary Syndrome Registry (CARDIO-CCH). Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Ther. 2019;28(3):14-20. (In Russ.)]. doi: 10.32756/0869-5490-2019-3-14-20.
8. Mazur NA, Lomonosova AA, Zolozova EA, et al. Antiaggregant therapy and reduction of high residual platelet reactivity. Russian Journal of Cardiology. 2012;4(96):74-78. (In Russ.).
9. Baturin VA, Ivanova AV, Muravyev KA, et al. Ethnic characteristics of antiaggregant action of acetylsalicylic acid in residents of Stavropol territory. Medical News of North Caucasus. 2020;15(1):68-71. (In Russ.). doi: 10.14300/mnnc.2020.15015/
Review
For citations:
Baturin V.A., Ivanova A.V., Tsarukyan A.A., Muravyov K.A. Features of aggregometry indicators in male residents of the Stavropol Territory — representatives of the Russian and Armenian ethnic groups receiving hospital treatment. Pharmacogenetics and Pharmacogenomics. 2024;(1):14-19. (In Russ.) https://doi.org/10.37489/2588-0527-2024-1-14-19. EDN: CSRASK